Elimination of daptomycin in a patient with acute renal failure undergoing extended daily dialysis [5]

Journal of Antimicrobial Chemotherapy

Volumn 61, Issue 1, 2008, Pages 224-225

  Burkhardt, Olaf ^a   Joukhadar, Christian ^b   Traunmüller, Friederike ^b   Hadem, Johannes ^a   Welte, Tobias ^a   Kielstein, Jan T ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

^b J & P Medical Research Ltd   (Austria)

Author keywords

Endocarditis; Gram positive infections; Renal replacement therapy

Indexed keywords

CIPROFLOXACIN; DAPTOMYCIN; TAZOBACTAM; VANCOMYCIN;

ACUTE KIDNEY FAILURE; AGED; AORTA VALVE DISEASE; AREA UNDER THE CURVE; ARTIFICIAL KIDNEY; BACTERIAL ENDOCARDITIS; BLOOD CULTURE; CASE REPORT; CONTINUOUS HEMODIALYSIS; DIALYSATE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG ELIMINATION; DRUG HALF LIFE; DRUG INFUSION; HUMAN; INTENSIVE CARE UNIT; KIDNEY BLOOD FLOW; LETTER; MALE; MAXIMUM PLASMA CONCENTRATION; MULTIDRUG RESISTANCE; SEPTIC SHOCK; SINGLE DRUG DOSE; STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS INFECTION; TIME TO MAXIMUM PLASMA CONCENTRATION; VANCOMYCIN RESISTANT ENTEROCOCCUS;

AGED; ANTI-BACTERIAL AGENTS; DAPTOMYCIN; HUMANS; KIDNEY FAILURE, ACUTE; MALE; METABOLIC DETOXICATION, DRUG; RENAL DIALYSIS; SHOCK, SEPTIC;

EID: 37549026164     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkm405     Document Type: Letter

References (8)

1. Johnson A. Daptomycin in the treatment of skin, soft-tissue and invasive infections due to Gram-positive bacteria. Future Microbiol 2006; 1: 255-65.
2. Dvorchik B, Arbeit RD, Chung J et al. Population pharmacokinetics of daptomycin. Antimicrob Agents Chemother 2004; 48: 2799-807.
3. Fliser D, Kielstein JT. Technology insight: Treatment of renal failure in the intensive care unit with extended dialysis. Nat Clin Pract Nephrol 2006; 2: 32-9.
4. Czock D, Husig-Linde C, Langhoff A et al. Pharmacokinetics of moxifloxacin and levofloxacin in intensive care unit patients who have acute renal failure and undergo extended daily dialysis. Clin J Am Soc Nephrol 2006; 1: 1263-8.
5. Kielstein JT, Czock D, Schopke T et al. Pharmacokinetics and total elimination of meropenem and vancomycin in intensive care unit patients undergoing extended daily dialysis. Crit Care Med 2006; 34: 51-6.
6. Dvorchik BH, Brazier D, DeBruin MF et al. Daptomycin pharmacokinetics and safety following administration of escalating doses once daily to healthy subjects. Antimicrob Agents Chemother 2003; 47: 1318-23.
7. Churchwell MD, Pasko DA, Mueller BA. Daptomycin clearance during modeled continuous renal replacement therapy. Blood Purif 2006; 24: 548-54.
8. Pankuch GA, Jacobs MR, Appelbaum PC. Postantibiotic effects of daptomycin against 14 staphylococcal and pneumococcal clinical isolates. Antimicrob Agents Chemother 2003; 47: 3012-4.